Bupropion as a modulator of drug activity
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Claims27
A method of treating major depressive disorder, comprising orally administering a combination of bupropion and dextromethorphan twice a day to a human being in need thereof for at least 8 consecutive days, wherein the combination comprises:
- about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in the free base form or another salt form;
- and
- about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form;
- wherein the combination is orally administered in a single dosage form comprising the bupropion and the dextromethorphan as the only therapeutically active compounds, which provides immediate release of dextromethorphan and sustained release of bupropion;
- and
- wherein the method is more effective in treating major depressive disorder than orally administering 105 mg of bupropion hydrochloride alone twice a day for at least 8 consecutive days.
A method of treating major depressive disorder, comprising orally administering a combination of bupropion and dextromethorphan once a day to a human being in need thereof for at least 8 consecutive days, wherein the combination comprises:
- about 210 mg of bupropion hydrochloride, or a molar equivalent amount of bupropion in the free base form or another salt form;
- and
- about 90 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form;
- wherein the combination is orally administered in a single dosage form comprising the bupropion and the dextromethorphan as the only therapeutically active compounds, which provides immediate release of dextromethorphan and sustained release of bupropion;
- and
- wherein the method is more effective in treating major depressive disorder than orally administering 210 mg of bupropion hydrochloride alone once a day for at least 8 consecutive days.
A method of treating major depressive disorder, comprising orally administering a combination of bupropion and dextromethorphan once a day or twice a day to a human being in need thereof for at least 8 consecutive days, wherein the combination comprises:
- about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide twice a day;
- about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide once a day;
- or
- an amount of a bupropion in the free base form or a salt form and an amount of dextromethorphan in the free base form or a salt form once a day or twice a day that provides, to the human being, about the same AUC0-24 of bupropion and about the same AUC0-24 of dextromethorphan as administering:
- about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide twice a day;
- wherein the combination is orally administered in a single dosage form comprising the bupropion and the dextromethorphan as the only therapeutically active compounds, which provides immediate release of dextromethorphan and sustained release of bupropion;
- and
- wherein the method is more effective in treating major depressive disorder than orally administering 105 mg of bupropion hydrochloride alone twice a day for at least 8 consecutive days.
Dependencies are inferred from the claim text.